Fig. 1.
Kaplan–Meier curves of baseline factors that did not affect overall survival (OS). a Effect of bone marrow blast count on OS (total cohort). b Effect of bone marrow blast count on OS (AZA first line). c Effect of age on OS. d Effect of WHO-AML type on OS. e Effect of white blood cell (WBC) count on OS. f Effect of WBC </≥15 G/l on OS. g Effect of achievement of EMA/FDA-target dose on OS. h Effect of azacitidine (AZA) schedule: 5 vs. 7 days of azacitidine per cycle on OS